Remove Development Remove Insulin Remove Life Science Remove Pharma Companies
article thumbnail

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Delveinsight

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. It is also known as insulin-dependent diabetes.

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare. It’s much needed.

Drugs 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly’s Tirzepatide Shows Promise in Treating Fatty Liver Disease

XTalks

The importance of identifying effective solutions for MASH is evident from the overall interest from the pharmaceutical industry and the competition in developing treatments for this serious liver condition. There are on-going studies to develop formulations with extended duration of action.

article thumbnail

LillyDirect: New Home Delivery Service for Eli Lilly’s Diabetes, Weight Loss and Migraine Drugs

XTalks

Related: Zepbound, Obesity Version of Eli Lilly’s Mounjaro, Finally Gets FDA Nod So far, LillyDirect provides support for 14 Lilly medicines, with 12 being different formulations and types of insulin. In addition to these and Zepbound, Lilly’s medication for migraine management, Emgality (galcanezumab), is also available through the website.

Drugs 59
article thumbnail

Pharma TV Ad Spending Trends: Companies in the Top Ten this Week

XTalks

Novo Nordisk’s oral GLP-1 diabetes drug Rybelsus (semaglutide) has been up in the ranks this year in pharma TV ad spending, with the Danish pharma company having spent $19.9 The drug is a human glucagon-like peptide-1 (GLP-1) agonist that functions to increase insulin secretion from the pancreas. million and $18.6

Insulin 104
article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98
article thumbnail

Pharma CEOs Grilled by Senate Committee About High Prescription Drug Prices

XTalks

Allocation of Profits, PBMs Under Fire The CEOs defended high prescription drug prices saying that a big chunk of pharma profits go towards funding the research and development of new medicines. Murphy interrogated this claim and specifically questioned the way companies allocate revenue.

Drugs 52